zetovar 10mg 20mg - search results

fresenius kabi sa-nv - ketovaline calcium 86 mg; lysine acetate 105 mg - eq. lysine 75 mg; histidine 38 mg; threonine 53 mg; tryptophan 23 mg; isoleucine calcium, alfa-, keto- 67 mg; leucine calcium, alfa-, keto- 101 mg; phenylalanine calcium, alfa-keto- 68 mg; hydroxymethionine calcium, alfa- 59 mg; tyrosine 30 mg - film-coated tablet - hydroxymethionine calcium, alfa- 59 mg; histidine 38 mg; lysine acetate 105 mg; threonine 53 mg; tryptophan 23 mg; tyrosine 30 mg; isoleucine calcium, alfa-, keto- 67 mg; leucine calcium, alfa-, keto- 101 mg; phenylalanine calcium, alfa-keto- 68 mg; valine calcium, alfa-, keto- 86 mg - amino acids, incl. combinations with polypeptides

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ketoclassic 3:1 bisk

ketocare foods ltd - not applicable

European Union - English - EMA (European Medicines Agency)

lopinavir/ritonavir mylan

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

European Union - English - EMA (European Medicines Agency)

selincro

h. lundbeck a/s - nalmefene hydrochloride dihydrate - alcohol-related disorders - drugs used in alcohol dependence - selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.